Revenue Recognition (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2025 USD ($) $ / shares	Mar. 31, 2024 USD ($) item $ / shares	Mar. 31, 2023 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Other assets	$ 40,897			$ 36,720
Deferred revenue	$ 37,262	$ 36,533		36,592	$ 35,740
Product
Approximate percentage of revenue collected within 9 months	90.00%
Extended billing collection period (in months)	6 months
Increased (decreased) revenues		2,100
(Increased) decreased net loss		$ 2,100
(Increased) decreased net loss per share | $ / shares		$ 0.02
Tests delivered in prior periods that were fully collected
Increased (decreased) revenues	$ 34,300	$ 33,700
(Increased) decreased net loss	$ 34,300	$ 33,700
(Increased) decreased net loss per share | $ / shares	$ 0.25	$ 0.28
Amounts not refunded to insurance carriers
Increased (decreased) revenues	$ 3,500	$ (1,500)
(Increased) decreased net loss	$ (3,500)	$ (1,500)
(Increased) decreased net loss per share | $ / shares	$ (0.03)	$ (0.01)
BGI Genomics
Proceeds from license agreement	$ 44,000
Agreement term	10 years
Revenue, remaining performance obligation	$ 6,000
Transaction price	50,000
Deferred revenue	17,200			$ 17,300
Prepaid royalties	20,000
BGI Genomics | License and related development services
Number of performance obligations | item		2
Revenue, remaining performance obligation		$ 24,000
BGI Genomics | Oncology assay interpretation services
Revenue recognized	$ 100		$ 300
Revenue, remaining performance obligation					$ 20,000